Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Issue 1 (January 2014)

• Record Type: Journal Article
• Authors: Kawajiri, Hidemi; Takashima, Tsutomu; Kashiwagi, Shinichiro; Noda, Satoru; Onoda, Naoyoshi; Hirakawa, Kosei
• Is Part Of: Expert review of anticancer therapy. Volume 15:Issue 1(2015)
• Page Start: 17
• Page End: 26
• Publication Date: 2014-01
• Subjects: Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/14737140.2015.992418
• Languages: English
• ISSNs: 1473-7140

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Overexpression of HER2 – found in approximately 15–20% of all breast cancers – is a negative prognostic factor. Although trastuzumab significantly improves the prognosis of HER2-positive breast cancer, half of the patients with metastatic breast cancer experience disease progression within 1 year. Pertuzumab is a novel HER2-targeted humanized monoclonal antibody that binds to the dimerization domain of HER2 and acts synergically with trastuzumab in inhibiting tumor progression. The CLEOPATRA trial demonstrated that adding pertuzumab to trastuzumab plus docetaxel significantly prolonged progression-free survival and overall survival without increasing severe adverse events. Conclusively, pertuzumab was approved by the US FDA in June 2012 for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer. Furthermore, various clinical trials to evaluate the efficacy and safety of pertuzumab combined with other cytotoxic agents are ongoing at present. Thus, pertuzumab has been becoming important for the treatment of patients with HER2-positive metastatic breast cancer.</p> </abstract>